Multicenter Evaluation of the VERSANT Hepatitis B Virus DNA 3.0 Assay

Journal of Clinical Microbiology

Volumn 42, Issue 2, 2004, Pages 800-806

  Yao, Joseph D C ^a   Beld, Marcel G H M ^b   Oon, Lynette Lin Ean ^c   Sherlock, Christopher H ^d   Germer, Jeffrey ^a   Menting, Sandra ^b   Thoe, Su Yun Se ^c   Merrick, Linda ^d   Ziermann, Rainer ^e   Surtihadi, Johan ^e   Hnatyszyn, H James ^e  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d ST PAUL S HOSPITAL   (Canada)

^e BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ANALYTIC METHOD; ARTICLE; ASSAY; EVALUATION; HEPATITIS B VIRUS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

DNA, VIRAL; GENETIC TECHNIQUES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 10744219691     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.2.800-806.2004     Document Type: Article

References (25)

1. Beld, M., R. Sentjens, S. Rebers, C. Weegink, J. Weel, C. Sol, and R. Boom. 2002. Performance of the new Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, version 2.0, assay. J. Clin. Microbiol. 40:788-793.
2. Berg, T., C. Sarrazin, E. Herrmann, H. Hinrichsen, T. Gerlach, R. Zachoval, B. Wiedenmann, U. Hopf, and S. Zeuzem. 2003. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37: 600-609.
3. Bland, J. M., and D. G. Altman. 1995. Comparing two methods of clinical measurement: a personal history. Int. J. Epidemiol. 24(Suppl. 1):S7-S14.
4. Conjeevaram, H. S., and A. S. Lok. 2003. Management of chronic hepatitis B. J. Hepatol. 38:S90-S103.
5. De Lamballerie, X., P. Gallian, and P. H. De Micen. 1995. Evaluation of a chemiluminescent molecular hybridization assay for the detection and quantitation of hepatitis B virus-DNA in serum. New Microbiol. 18:207-213.
6. The EASL Jury. 2003. EASL International Consensus Conference on Hepatitis B. J. Hepatol. 39:S3-S25.
7. Galan, M. V., D. Boyce, and S. C. Gordon. 2001. Current pharmacotherapy for hepatitis B infection. Expert Opin. Pharmacother. 2:1289-1298.
8. Gleaves, C. A., J. Welle, M. Campbell, T. Elbeik, V. Ng, P. E. Taylor, K. Kuramoto, S. Aceituno, E. Lewalski, B. Joppa, L. Sawyer, C. Schaper, D. McNairn, and T. Quinn. 2002. Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance. J. Clin. Virol. 25:205-216.
9. Hendricks, D. A., B. J. Stowe, B. S. Hoo, J. Kolberg, B. D. Irvine, P. D. Neuwald, M. S. Urdea, and R. P. Perrillo. 1995. Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. Am. J. Clin. Pathol. 104:537-546.
10. Kessler, H. H., K. Pierer, E. Dragon, H. Lackner, B. Santner, D. Stunzner, E. Stelzl, B. Waitzl, and E. Marth. 1998. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. Clin. Diagn. Virol. 9:37-43.
11. Krajden, M., J. Minor, L. Cork, and L. Comanor. 1998. Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays. J. Viral Hepat. 5:415-422.
12. Lai, C. L., M. Rosmawati, J. Lao, H. Van Vlierberghe, F. H. Anderson, N. Thomas, and D. Dehertogh. 2002. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123:1831-1838.
13. Lok, A. S. 2000. Hepatitis B infection: pathogenesis and management. J. Hepatol. 32:89-97.
14. Lok, A. S., M. G. Ghany, G. Watson, and B. Ayola. 1998. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J. Viral Hepat. 5:171-178.
15. Lok, A. S., E. J. Heathcote, and J. H. Hoofnagle. 2001. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 120:1828-1853.
16. Lopez, V. A., E. J. Bourne, M. W. Lutz, and L. D. Condreay. 2002. Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels. J. Clin. Microbiol. 40:1972-1976.
17. Marin, I. J., M. Poljak, K. Seme, V. Brinovec, M. Maticic, J. Meglic-Volkar, G. Lesnicar, and P. Gradisek. 2002. Comparative evaluation of three commercial assays for quantitative measurement of hepatitis B virus DNA in serum samples. Hepatogastroenterology 49:1390-1394.
18. Martinot-Peignoux, M., N. Boyer, M. Colombat, R. Akremi, B. N. Pham, S. Ollivier, C. Castelnau, D. Valla, C. Degott, and P. Marcellin. 2002. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J. Hepatol. 36:543-546.
19. Nolte, F. S. 1998. Branched DNA signal amplification for direct quantitation of nucleic acid sequences in clinical specimens. Adv. Clin. Chem. 33:201-235.
20. Pawlotsky, J. M. 2003. Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics. J. Hepatol. 39:S31-S35.
21. Pawlotsky, J. M. 2002. Molecular diagnosis of viral hepatitis. Gastroenterology 122:1554-1568.
22. Pawlotsky, J. M., A. Bastie, C. Hezode, I. Lonjon, F. Darthuy, J. Remire, and D. Dhumeaux. 2000. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. J. Virol. Methods 85:11-21.
23. Pumpens, P., E. Grens, and M. Nassal. 2002. Molecular epidemiology and immunology of hepatitis B virus infection: an update. Intervirology 45:218-232.
24. Wai, C. T., and A. S. Lok. 2002. Treatment of hepatitis B. J. Gastroenterol. 37:771-778.
25. World Health Organization Department of Communicable Diseases Surveillance and Response. 2002. Hepatitis B. WHO/CDS/CSR/LYO/2002.2: Hepatitis B:8. World Health Organization, Geneva, Switzerland. [Online.] http://www.who.int/emc-documents/hepatitis/docs/whocdsrlyo20022/index.html.